ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks

被引：0
|
作者：
HoWon Lee
Amgad N. Makaryus
Samy I. McFarlane
机构：
来源：
Current Diabetes Reports | 2009年 / 9卷 / 3期
关键词：
Chronic Heart Failure; Valsartan; Ramipril; Candesartan; Telmisartan;
D O I：
10.1007/s11892-009-0030-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 187
页数：2
相关论文
共 50 条
  • [1] ONTARGET study of telmisartan, ramipril, or both in high-risk patients
    Ram, C. Venkata S.
    CURRENT HYPERTENSION REPORTS, 2008, 10 (05) : 345 - 348
  • [2] ONTARGET study of telmisartan, ramipril, or both in high-risk patients
    C. Venkata S. Ram
    Current Hypertension Reports, 2008, 10 : 345 - 348
  • [3] Review of ONTARGET: Treating Patients at High Risk for Vascular Events with Telmisartan, Ramipril, or Both
    Guthrie, Robert M.
    POSTGRADUATE MEDICINE, 2009, 121 (02) : 202 - 204
  • [4] Telmisartan, Ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial
    Lyakishev, A. A.
    KARDIOLOGIYA, 2008, 48 (05) : 72 - 72
  • [5] Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data
    Yu Li-tian
    Zhu Jun
    Tan Hui-qiong
    Wang Guo-gan
    Teo, Koon K.
    Liu Li-sheng
    CHINESE MEDICAL JOURNAL, 2011, 124 (12) : 1763 - 1768
  • [6] Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk Results From the ONTARGET and TRANSCEND Studies
    Tobe, Sheldon W.
    Clase, Catherine M.
    Gao, Peggy
    McQueen, Matthew
    Grosshennig, Anja
    Wang, Xingyu
    Teo, Koon K.
    Yusuf, Salim
    Mann, Johannes F. E.
    CIRCULATION, 2011, 123 (10) : 1098 - U235
  • [7] Telmisartan is as affective as ramipril in preventing cardiovascular events in high-risk patients, but no additional protective benefit was achieved if ramipril and telmisartan are combined - ONTARGET trial
    不详
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 604 - 605
  • [8] ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure
    不详
    CARDIOVASCULAR JOURNAL OF AFRICA, 2008, 19 (02) : 108 - 109
  • [9] The rationale for choosing telmisartan and ramipril in the ONTARGET programme
    Unger, Thomas
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2009, 11 (0F) : F3 - F8
  • [10] Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials
    Boehm, Michael
    Baumhaekel, Magnus
    Teo, Koon
    Sleight, Peter
    Probstfield, Jeffrey
    Gao, Peggy
    Mann, Johannes F.
    Diaz, Rafael
    Dagenais, Gilles R.
    Jennings, Garry L. R.
    Liu, Lisheng
    Jansky, Petr
    Yusuf, Salim
    CIRCULATION, 2010, 121 (12) : 1439 - U114
12345